Business
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C., May 05, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a1464f621abd02d24b4c969189ff2735"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JldlIicfkphOPoB19lsPxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/a1464f621abd02d24b4c969189ff2735","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YtfP38XYIksyWnBpnWH8bw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/a1464f621abd02d24b4c969189ff2735","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association for the Study of the Liver Congress 2026 -","length":230,"tagName":"p","attribs":{}},{"type":"text","content":"- Advanced PBGENE-DMD toward clinical evaluation in the Phase 1/2 FUNCTION-DMD trial following U.S. FDA IND clearance and Fast Track designation; First clinical trial site activated and enrolling patients -","length":206,"tagName":"p","attribs":{}},{"type":"text","content":"- Cash balance of $125.8 million including cash, cash equivalents and restricted cash as of March 31, 2026, expected to enable data milestones from two wholly owned clinical stage in vivo gene editing programs – PBGENE-HBV and PBGENE-DMD through 2028 -","length":252,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., May 05, 2026--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":355,"tagName":"p"},{"type":"text","content":""During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts in the ELIMINATE-B trial and drove PBGENE-DMD through Investigational New Drug (IND) approval and activated our first clinical site as we prepare to dose the first patient in the FUNCTION...